PSMA Antikörper (AA 44-750) (PE)
Kurzübersicht für PSMA Antikörper (AA 44-750) (PE) (ABIN614249)
Target
Alle PSMA (FOLH1) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Bindungsspezifität
- AA 44-750
-
Spezifität
- This antibody recognizes extracellular domain of Glutamate Carboxypeptidase II (NAALADase, FOLH1, PSMA), an approximately 95-110 kDa transmembrane glycoprotein expressed mainly in tumour neovasculatures, nervous system and jejunum, which is an important prostate tumour marker.
-
Kreuzreaktivität (Details)
- Species reactivity (tested):Human.
-
Isotyp
- IgG1
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 0.1 mg/mL
-
Buffer
- Phosphate buffered saline (PBS), 15 mM Sodium Azide, 0.2 % (w/v) high-grade protease free BSA
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
-
-
: "Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer." in: The EMBO journal, Vol. 25, Issue 6, pp. 1375-84, (2006) (PubMed).
: "Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, Issue 17, pp. 5981-6, (2005) (PubMed).
-
-
- PSMA (FOLH1) (Folate Hydrolase (Prostate-Specific Membrane Antigen) 1 (FOLH1))
-
Andere Bezeichnung
- PSMA / FOLH1
-
Hintergrund
- Glutamate carboxypeptidase II (GCPII), also known as N-acetyl-alpha-linked acidic dipeptidase I (NAALADase I), folate hydrolase (FOLH1), and prostate-specific membrane antigen (PSMA), is an approximately 95-110 kDa type II transmembrane glycoprotein expressed in various tissues. In nervous system GCPII cleaves abundant N-acetylaspartylglutamate, which is released from neurons in a calcium-dependent manner, to N-acetylaspartate and glutamate. As immoderate glutamate concentration is neurotoxic, GCPII contributes to pathological conditions regarding e.g. Alzheimer´s disease, Huntington´s disease, epilepsy, schizophrenia, stroke or neuropathic pain and appears to be an interesting therapeutic target. In jejunum GCPII hydrolyzes pteroylpoly-gamma-glutamate to folate and glutamate, enabling folate to be absorbed by gastrointestinal tract. GCPII, which is present in a number of tissues at low levels, is overexpressed in neovasculature of most solid tumours and is a target enzyme for diagnosis and treatment of prostate cancer. Normal human prostate express more mRNA coding for a cytosolic GCPII form truncated at the N-terminus (PSM´) than mRNA for membrane-bound GCPII, and this ratio is reversed upon malignant transformation.Synonyms: FOLH, Folate hydrolase 1, Folylpoly-gamma-glutamate carboxypeptidase, GCP2, Glutamate carboxypeptidase 2, Glutamate carboxypeptidase II, Membrane glutamate carboxypeptidase, N-acetylated-alpha-linked acidic dipeptidase I, NAALAD1, NAALAdase, PSM, Prostate-specific membrane antigen, Pteroylpoly-gamma-glutamate carboxypeptidase
-
Gen-ID
- 2346
Target
-